Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer

V. Kulda, O. Topolcan, R. Kucera, M. Kripnerova, K. Srbecka, M. Hora, O. Hes, J. Klecka, V. Babuska, M. Rousarova, V. Benson, M. Pesta,

. 2016 ; 36 (9) : 4787-93.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013530

BACKGROUND/AIM: Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy. PATIENTS AND METHODS: The study group consisted of 108 patients who underwent radical prostatectomy. PSA was measured in peripheral blood collected preoperativelly. The expression of TMPRSS2-ERG transcript and the expression of miR-23b, miR-26a and miR-221 in formalin-fixed, paraffin-embedded (FFPE) tumor tissues was analyzed by reverse transcription (RT) real-time polymerase chain reaction (PCR). RESULTS: Significantly shorter time to recurrence was observed in patients with high expression of TMPRSS2-ERG (p=0.0020). High levels of preoperative PSA (>10.0 ng/ml) proved to be marker of shorter time to recurrence (p=0.0153). The most promising marker of the risk of recurrence after radical prostatectomy was a combination of high level of preoperative serum PSA and high expression of TMPRSS2-ERG fusion transcript in tumor tissue (p=0.0001). CONCLUSION: A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013530
003      
CZ-PrNML
005      
20171102092229.0
007      
ta
008      
170413s2016 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.11037 $2 doi
035    __
$a (PubMed)27630329
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
245    10
$a Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer / $c V. Kulda, O. Topolcan, R. Kucera, M. Kripnerova, K. Srbecka, M. Hora, O. Hes, J. Klecka, V. Babuska, M. Rousarova, V. Benson, M. Pesta,
520    9_
$a BACKGROUND/AIM: Current research of prostate cancer (PCa) offers a promising way of identifying patients with adverse prognosis who do benefit from radical treatment that can affect quality of life as resections are associated with numerous side-effects. The aim of our study was to evaluate the relationship of TMPRSS2-ERG fusion gene status, tumor tissue prostate-specific antigen (PSA), prostate cancer antigen 3 (PCA3), miR-23b, miR-26a and miR-221 expression levels in combination with preoperative serum PSA level to the risk of PCa recurrence after radical prostatectomy. PATIENTS AND METHODS: The study group consisted of 108 patients who underwent radical prostatectomy. PSA was measured in peripheral blood collected preoperativelly. The expression of TMPRSS2-ERG transcript and the expression of miR-23b, miR-26a and miR-221 in formalin-fixed, paraffin-embedded (FFPE) tumor tissues was analyzed by reverse transcription (RT) real-time polymerase chain reaction (PCR). RESULTS: Significantly shorter time to recurrence was observed in patients with high expression of TMPRSS2-ERG (p=0.0020). High levels of preoperative PSA (>10.0 ng/ml) proved to be marker of shorter time to recurrence (p=0.0153). The most promising marker of the risk of recurrence after radical prostatectomy was a combination of high level of preoperative serum PSA and high expression of TMPRSS2-ERG fusion transcript in tumor tissue (p=0.0001). CONCLUSION: A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antigeny nádorové $x biosyntéza $x genetika $7 D000951
650    _2
$a nádorové biomarkery $x biosyntéza $x krev $x genetika $7 D014408
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x biosyntéza $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x krev $x genetika $x patologie $7 D009364
650    _2
$a fúzní onkogenní proteiny $x genetika $7 D015514
650    _2
$a zalévání tkání do parafínu $7 D016612
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a prostata $x patologie $7 D011467
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a prostatektomie $7 D011468
650    _2
$a nádory prostaty $x krev $x genetika $x patologie $x chirurgie $7 D011471
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
700    1_
$a Topolcan, Ondrej $u Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Kucera, Radek $u Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Kripnerova, Michaela $u Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Srbecká, Kristýna $7 xx0218151 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Hora, Milan $u Department of Urology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Hes, Ondrej $u Department of Pathology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Klecka, Jiri $u Urocentrum Plzen, Pilsen, Czech Republic.
700    1_
$a Babuska, Vaclav $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Rousarova, Milena $u Department of Nuclear Medicine - Immunoanalytic Laboratory, University Hospital in Pilsen, Pilsen, Czech Republic.
700    1_
$a Benson, Veronika $u Institute of Microbiology, v.v.i., Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic martin.pesta@lfp.cuni.cz.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 36, č. 9 (2016), s. 4787-93
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27630329 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20171102092322 $b ABA008
999    __
$a ok $b bmc $g 1199995 $s 974308
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 36 $c 9 $d 4787-93 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace